Word for Pharming Group NV in mid-January of an action date regarding the supplemental BLA for the C1-esterase inhibitor Ruconest, followed by news four days later that Biocryst Pharmaceuticals Inc. and Idera Pharmaceuticals Inc. will merge, added yet another shift in the hereditary angioedema (HAE) space.